Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The prognostic significance of lung function in stable heart failure outpatients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Retinal arteriolar wall-to-lumen ratios at 16-17 years in the Copenhagen Child Cohort 2000 Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Steven E Nissen
  • Ricardo E Dent-Acosta
  • Robert S Rosenson
  • Erik Stroes
  • Naveed Sattar
  • David Preiss
  • G B John Mancini
  • Christie M Ballantyne
  • Alberico Catapano
  • Ioanna Gouni-Berthold
  • Evan A Stein
  • Allen Xue
  • Scott M Wasserman
  • Rob Scott
  • Paul D Thompson
  • GAUSS-3 Investigators
Vis graf over relationer

Statins are the accepted standard for lowering low-density lipoprotein cholesterol (LDL-C). However, 5% to 10% of statin-treated patients report intolerance, mostly due to muscle-related adverse effects. Challenges exist to objective identification of statin-intolerant patients. Evolocumab is a monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), resulting in marked LDL-C reduction. We report the design of Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3), a phase 3, multicenter, randomized, double-blind, ezetimibe-controlled study to compare effectiveness of 24 weeks of evolocumab 420 mg monthly vs ezetimibe 10 mg daily in hypercholesterolemic patients unable to tolerate an effective statin dose. The study incorporates a novel atorvastatin-controlled, double-blind, crossover phase to objectively identify statin intolerance. Eligible patients had LDL-C above the National Cholesterol Education Project Adult Treatment Panel III target level for the appropriate coronary heart disease risk category and were unable to tolerate ≥3 statins or 2 statins (one of which was atorvastatin ≤10 mg/d) or had a history of marked creatine kinase elevation accompanied by muscle symptoms while on 1 statin. This trial has 2 co-primary endpoints: mean percent change from baseline in LDL-C at weeks 22 and 24 and percent change from baseline in LDL-C at week 24. Key secondary efficacy endpoints include change from baseline in LDL-C, percent of patients attaining LDL-C <70 mg/dL (1.81 mmol/L), and percent change from baseline in total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B. Recruitment of 511 patients was completed on November 28, 2014.

OriginalsprogEngelsk
TidsskriftClinical Cardiology
Vol/bind39
Udgave nummer3
Sider (fra-til)137-44
Antal sider8
ISSN0160-9289
DOI
StatusUdgivet - mar. 2016

ID: 49237151